Myasthenia gravis and myasthenic crisis represents a major medical and neurological emergency characterized by antibody-mediated destruction of postsynaptic receptor complexes at the neuromuscular junction ^{1, 2}. Myasthenia gravis (MG) manifests as fatigable weakness that characteristically worsens with exertion and improves with rest ^{4, 5}. When this weakness involves the intercostal muscles and diaphragm, patients can rapidly progress into a myasthenic crisis (MCr), defined as acute respiratory failure requiring invasive or non-invasive mechanical ventilation ¹. Affecting approximately 15% to 20% of patients with generalized MG—typically within the first two to three years of disease onset—crisis demands immediate recognition, intensive care unit admission, airway protection, and prompt immunomodulatory rescue therapy ^{1, 2}.

1. Etiology & Risk Factors

• Autoimmune Pathogenesis: Loss of immunological tolerance resulting in T-cell-dependent, B-cell-mediated production of pathogenic autoantibodies directed against postsynaptic membrane components ^{4, 5}.
• Thymic Abnormalities: Thymic hyperplasia is present in 65% of patients with early-onset generalized MG, while thymoma accounts for approximately 10% to 15% of cases and is strongly linked to anti-acetylcholine receptor (anti-AChR) seropositivity ^{1, 2}.
• Precipitating Triggers of Myasthenic Crisis: Respiratory tract infections (most common), surgery, emotional stress, pregnancy, tapering of immunosuppressive medications, and exposure to triggering drugs ^{1, 2}.
• Pharmacological Triggers: Aminoglycosides, fluoroquinolones, macrolides, magnesium sulfate, beta-blockers, penicillamine, immune checkpoint inhibitors, and botulinum toxin ^{2, 3}.
• Genetic Predisposition: Association with specific human leukocyte antigen (HLA) alleles, notably HLA-B8 and DR3 in early-onset Caucasian populations ⁴.

2. Pathophysiology

The core pathomechanism of myasthenia gravis involves an antibody-mediated attack on the postsynaptic neuromuscular junction. In anti-AChR antibody-positive disease, high-affinity IgG antibodies bind to the extracellular domain of the nicotinic acetylcholine receptor (nAChR). This binding initiates three synergistic destructive processes: complement-mediated lysis via the Membrane Attack Complex (MAC) targeting junctional folds, accelerated receptor internalization and degradation (antigenic modulation), and direct blockade of acetylcholine binding sites. Consequently, the density of functional postsynaptic receptors plummets, causing subthreshold end-plate potentials that fail to trigger muscle action potentials, culminating in clinical fatigability and progressive weakness. In anti-MuSK (Muscle-Specific Kinase) antibody-positive cases, non-complement-fixing IgG4 antibodies disrupt agrin-LRP4-MuSK signaling pathways, preventing normal clustering of AChRs without classical complement deposition. When severe bulbar or respiratory muscle involvement precipitates a myasthenic crisis, alveolar hypoventilation ensues, driven by profound failure of neuromuscular transmission in the diaphragm, intercostal, and upper airway accessory muscles ^{1, 2, 4}.

3. Clinical Presentation & Clinical Signs

• History & Cardinal Symptoms: Fluctuating skeletal muscle weakness that is characteristically minimal upon waking and progressively worsens toward the end of the day or with sustained physical activity ^{4, 5}. Ocular symptoms include asymmetric ptosis and binocular diplopia due to extraocular muscle involvement ^{1, 2}. Bulbar manifestations include dysarthria, nasal speech, chewing fatigue, and dysphagia with a high risk of aspiration ^{1, 2}. Limb weakness typically presents as proximal, symmetrical weakness (e.g., difficulty climbing stairs or lifting heavy objects) ⁴.
• Physical Examination & Named Clinical Signs:
  • Cogan's Lid Twitch Sign: Brief upward overshoot of the upper eyelid after looking down for 15 seconds and returning to primary gaze.
  • Ice Pack Test: Application of an ice pack to a ptotic eyelid for 2 minutes produces significant improvement in ptosis due to decreased acetylcholinesterase activity at lower temperatures.
  • Simpson Test: Sustained upward gaze for 30–60 seconds provokes progressive, measurable worsening of ptosis.
  • Head Drop Sign: Weakness of neck extensor muscles leading to an inability to lift the head against gravity.
  • Preserved Reflexes & Sensation: Deep tendon reflexes remain completely intact and sensory examination is entirely normal, ruling out peripheral neuropathies ⁵.

4. Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

5. Staging, Classification & Clinical Scoring Systems

6. Differential Diagnosis

7. Management & Treatment Protocol

• Initial Stabilization & Resuscitation: Continuous monitoring of ventilatory parameters (forced vital capacity [FVC] and negative inspiratory force [NIF]). Elective or emergency endotracheal intubation is indicated if FVC drops below 15–20 mL/kg, maximum inspiratory pressure < -30 cmH2O, or in the setting of acute hypercapnic respiratory failure and severe bulbar exhaustion ^{1, 2}. Elimination of all precipitating triggers (aggressive antibiotic therapy for pulmonary infections) ¹.
• First-Line Medical / Pharmacological Therapy (Adult Dosing):
  • Symptomatic Treatment: Pyridostigmine oral tablets 60 mg orally every 3 to 6 hours (titrated to maximum 120 mg every 3 hours based on clinical response and tolerability) ^{2, 7}. Note: Temporarily hold or reduce acetylcholinesterase inhibitors during acute mechanical ventilation to minimize excessive bronchial secretions.
  • Rapid Rescue Immunomodulation in Crisis: Plasma Exchange (PLEX) administered over 5 sessions every other day, or Intravenous Immunoglobulin (IVIG) dosed at 0.4 g/kg/day for 5 consecutive days (total 2 g/kg). PLEX is often favored for rapid clinical reversal ^{1, 2, 5}.
  • Long-term Immunosuppression: Oral Prednisolone initiated at low dose (e.g., 10 mg daily) and gradually titrated upwards to avoid initial transient worsening, combined with steroid-sparing agents such as Azathioprine (2–3 mg/kg/day) or Mycophenolate Mofetil ².

• Surgical / Interventional Indications:
  • Thymectomy: Indicated for all patients with generalized anti-AChR antibody-positive myasthenia gravis between puberty and age 60, and mandatory in patients with radiologically confirmed thymoma regardless of age, to induce long-term remission and reduce immunosuppressive requirements ^{1, 2}.

8. Complications & Prognosis

• Acute Complications: Ventilator-associated pneumonia, barotrauma, critical illness myopathy/neuropathy, venous thromboembolism, medication-induced acute steroid myopathy, and severe autonomic instability during crisis ^{1, 2}.
• Chronic Complications: Chronic respiratory insufficiency, aspiration pneumonitis, adverse effects of long-term corticosteroids (osteoporosis, weight gain, cataracts, hyperglycemia), and immunosuppressant-related bone marrow suppression or hepatotoxicity ^{2, 4}.
• Prognosis: With modern intensive care management, non-invasive ventilation, and rapid immunomodulatory rescue therapy, the mortality rate for myasthenic crisis has fallen below 5% in specialized centers, though elderly patients and those with severe baseline comorbidities remain at significantly higher risk ³. Most patients are successfully weaned from mechanical ventilation within one month and return to baseline functional status following appropriate thymectomy and targeted immunotherapy ¹.